Company Overview

Cardiol Therapeutics Inc. is a Canada‑based clinical‑stage pharmaceutical company focused on developing anti‑inflammatory and anti‑fibrotic therapies for the treatment of cardiovascular diseases. The company operates within the biopharmaceutical and cardiovascular therapeutics industries, with a specific emphasis on heart failure and inflammatory heart conditions. Its activities are primarily research‑ and development‑oriented, and it does not generate commercial product revenue as of the latest publicly available filings.

The company’s core product candidate is CardiolRx™, a pharmaceutically manufactured cannabidiol formulation under clinical investigation for recurrent pericarditis and acute myocarditis. Cardiol Therapeutics positions itself uniquely by targeting inflammation and fibrosis pathways in heart disease using a non‑psychoactive cannabinoid‑based approach. The company was incorporated in 2017 and has since evolved from early preclinical research into a clinical‑stage organization with multiple mid‑stage clinical trials in progress.

Business Operations

Cardiol Therapeutics operates as a single reportable business segment focused on cardiovascular drug development, encompassing discovery, formulation, and clinical testing. The company’s operations are centered on advancing its lead drug candidates through Phase II and Phase III clinical trials, regulatory engagement, and intellectual property development. All revenue to date has been derived from financing activities rather than product sales, consistent with its clinical‑stage status.

Operationally, the company conducts clinical trials primarily in North America, leveraging third‑party contract research organizations, academic medical centers, and manufacturing partners. Cardiol Therapeutics controls proprietary drug formulations and related intellectual property and operates through its wholly owned U.S. subsidiary, Cardiol Therapeutics (USA), Inc., which supports clinical development and regulatory activities in the United States. No material joint ventures have been disclosed in public filings.

Strategic Position & Investments

Strategically, Cardiol Therapeutics is focused on advancing CardiolRx™ through late‑stage clinical development with the objective of addressing unmet needs in inflammatory heart disease. Growth initiatives are centered on clinical trial execution, regulatory milestone achievement, and potential future commercialization partnerships. The company has also advanced CRD‑38, a subcutaneous cannabidiol formulation, in earlier‑stage development for heart failure indications.

The company has not reported any material acquisitions or equity investments in other operating businesses. Its capital allocation strategy has been primarily directed toward internal research and development, clinical trials, and maintaining intellectual property protection. Public disclosures indicate that strategic alternatives such as licensing or commercialization partnerships may be evaluated in the future; however, specific transactions have not been confirmed. Data inconclusive based on available public sources regarding additional portfolio investments beyond disclosed development programs.

Geographic Footprint

Cardiol Therapeutics is headquartered in Oakville, Ontario, Canada, and maintains a growing operational presence in the United States through its wholly owned subsidiary. Clinical trial activities span multiple sites across Canada and the United States, reflecting the company’s focus on North American regulatory pathways and patient populations.

While the company does not currently report commercial operations outside North America, its clinical programs and regulatory strategy are designed to support potential future expansion into European and other international markets. Its geographic footprint remains primarily research‑driven rather than sales‑driven at this stage of development.

Leadership & Governance

Cardiol Therapeutics is led by an executive team with experience in pharmaceutical development, capital markets, and corporate governance. The leadership emphasizes a strategy centered on scientific rigor, regulatory discipline, and addressing unmet clinical needs in cardiovascular medicine.

Key executives include:

• David G. Elsley – President & Chief Executive Officer
• Andrew Hamer – Executive Chair
• Phillip Scott – Chief Financial Officer
• Joseph C. Parise – Chief Medical Officer

The board and management team collectively guide the company’s long‑term strategy, clinical development priorities, and capital allocation decisions. Where executive role descriptions or tenure differ across disclosures, data inconclusive based on available public sources.